Kiniksa Pharmaceuticals LtdNASDAQ:KNSA
- LAST PRICE21.2900
- TODAY'S CHANGE (%)-0.5200 (-2.3842%)
- Bid / Lots20.2000/ 1
- Ask / Lots22.1500/ 1
- Open / Previous Close21.9000 / 21.8100
- Day Range
- 52 Week Range
- Volume259,867
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KNSA |
|---|---|---|
| 09:32 ET | 9593 | 21.955 |
| 09:33 ET | 100 | 21.815 |
| 09:35 ET | 200 | 21.815 |
| 09:37 ET | 300 | 21.61 |
| 09:42 ET | 200 | 21.65 |
| 09:44 ET | 100 | 21.65 |
| 09:46 ET | 1600 | 21.615 |
| 09:48 ET | 200 | 21.66 |
| 10:00 ET | 700 | 21.72 |
| 10:02 ET | 400 | 21.74 |
| 10:06 ET | 785 | 21.68 |
| 10:08 ET | 1210 | 21.69 |
| 10:09 ET | 100 | 21.65 |
| 10:11 ET | 100 | 21.65 |
| 10:13 ET | 1300 | 21.64 |
| 10:15 ET | 4500 | 21.42 |
| 10:18 ET | 900 | 21.55 |
| 10:20 ET | 200 | 21.525 |
| 10:22 ET | 205 | 21.46 |
| 10:24 ET | 100 | 21.385 |
| 10:26 ET | 800 | 21.33 |
| 10:27 ET | 100 | 21.345 |
| 10:29 ET | 100 | 21.345 |
| 10:31 ET | 200 | 21.33 |
| 10:36 ET | 100 | 21.325 |
| 10:38 ET | 1325 | 21.32 |
| 10:40 ET | 100 | 21.315 |
| 10:44 ET | 594 | 21.26 |
| 10:45 ET | 300 | 21.34 |
| 10:47 ET | 2432 | 21.21 |
| 10:49 ET | 2505 | 21.24 |
| 10:51 ET | 100 | 21.19 |
| 10:56 ET | 100 | 21.155 |
| 10:58 ET | 200 | 21.16 |
| 11:00 ET | 1220 | 21.23 |
| 11:02 ET | 400 | 21.25 |
| 11:03 ET | 200 | 21.27 |
| 11:05 ET | 300 | 21.23 |
| 11:09 ET | 100 | 21.24 |
| 11:12 ET | 300 | 21.23 |
| 11:18 ET | 4735 | 21.385 |
| 11:20 ET | 1600 | 21.5 |
| 11:23 ET | 200 | 21.54 |
| 11:25 ET | 710 | 21.48 |
| 11:32 ET | 200 | 21.57 |
| 11:36 ET | 100 | 21.565 |
| 11:38 ET | 300 | 21.565 |
| 11:39 ET | 200 | 21.47 |
| 11:43 ET | 100 | 21.48 |
| 11:48 ET | 920 | 21.55 |
| 11:52 ET | 3107 | 21.4025 |
| 11:54 ET | 100 | 21.395 |
| 11:56 ET | 100 | 21.47 |
| 11:57 ET | 300 | 21.5 |
| 11:59 ET | 566 | 21.475 |
| 12:01 ET | 100 | 21.5 |
| 12:08 ET | 2232 | 21.48 |
| 12:10 ET | 100 | 21.52 |
| 12:12 ET | 400 | 21.505 |
| 12:14 ET | 3835 | 21.39 |
| 12:17 ET | 411 | 21.4 |
| 12:19 ET | 100 | 21.41 |
| 12:21 ET | 100 | 21.41 |
| 12:24 ET | 100 | 21.41 |
| 12:26 ET | 2420 | 21.41 |
| 12:30 ET | 1668 | 21.415 |
| 12:32 ET | 3080 | 21.43 |
| 12:35 ET | 100 | 21.47 |
| 12:37 ET | 3827 | 21.4 |
| 12:39 ET | 161 | 21.4 |
| 12:42 ET | 200 | 21.36 |
| 12:44 ET | 1295 | 21.335 |
| 12:46 ET | 100 | 21.345 |
| 12:48 ET | 900 | 21.38 |
| 12:51 ET | 100 | 21.38 |
| 12:55 ET | 200 | 21.38 |
| 12:57 ET | 1954 | 21.36 |
| 01:00 ET | 322 | 21.34 |
| 01:02 ET | 763 | 21.36 |
| 01:04 ET | 1200 | 21.34 |
| 01:06 ET | 518 | 21.325 |
| 01:08 ET | 300 | 21.345 |
| 01:09 ET | 400 | 21.345 |
| 01:11 ET | 1575 | 21.39 |
| 01:15 ET | 725 | 21.34 |
| 01:18 ET | 200 | 21.34 |
| 01:20 ET | 572 | 21.36 |
| 01:22 ET | 400 | 21.355 |
| 01:24 ET | 1900 | 21.36 |
| 01:26 ET | 1788 | 21.36 |
| 01:27 ET | 1171 | 21.4 |
| 01:29 ET | 300 | 21.4 |
| 01:33 ET | 1100 | 21.4 |
| 01:36 ET | 150 | 21.4 |
| 01:40 ET | 400 | 21.37 |
| 01:42 ET | 200 | 21.355 |
| 01:44 ET | 100 | 21.355 |
| 01:45 ET | 100 | 21.355 |
| 01:47 ET | 100 | 21.36 |
| 01:49 ET | 100 | 21.36 |
| 01:51 ET | 100 | 21.34 |
| 01:56 ET | 100 | 21.335 |
| 01:58 ET | 500 | 21.28 |
| 02:02 ET | 100 | 21.28 |
| 02:03 ET | 200 | 21.25 |
| 02:05 ET | 300 | 21.235 |
| 02:07 ET | 200 | 21.2 |
| 02:09 ET | 505 | 21.25 |
| 02:12 ET | 100 | 21.26 |
| 02:16 ET | 500 | 21.2 |
| 02:20 ET | 100 | 21.195 |
| 02:21 ET | 405 | 21.13 |
| 02:23 ET | 292 | 21.16 |
| 02:25 ET | 200 | 21.14 |
| 02:27 ET | 417 | 21.18 |
| 02:30 ET | 250 | 21.18 |
| 02:32 ET | 200 | 21.18 |
| 02:34 ET | 702 | 21.24 |
| 02:36 ET | 200 | 21.3 |
| 02:38 ET | 639 | 21.3146 |
| 02:39 ET | 100 | 21.32 |
| 02:41 ET | 400 | 21.36 |
| 02:43 ET | 100 | 21.4 |
| 03:15 ET | 560 | 21.31 |
| 03:17 ET | 400 | 21.3 |
| 03:19 ET | 300 | 21.3 |
| 03:21 ET | 500 | 21.3 |
| 03:24 ET | 900 | 21.295 |
| 03:26 ET | 500 | 21.295 |
| 03:28 ET | 303 | 21.3 |
| 03:30 ET | 200 | 21.3 |
| 03:32 ET | 1501 | 21.355 |
| 03:33 ET | 300 | 21.33 |
| 03:35 ET | 200 | 21.32 |
| 03:37 ET | 800 | 21.33 |
| 03:39 ET | 200 | 21.35 |
| 03:42 ET | 100 | 21.33 |
| 03:44 ET | 500 | 21.325 |
| 03:46 ET | 4532 | 21.335 |
| 03:48 ET | 500 | 21.325 |
| 03:50 ET | 500 | 21.32 |
| 03:51 ET | 2082 | 21.34 |
| 03:53 ET | 1000 | 21.305 |
| 03:55 ET | 1809 | 21.36 |
| 03:57 ET | 3293 | 21.36 |
| 04:00 ET | 50712 | 21.29 |
Nov 12, 2024
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 5, 2024
DJ Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan, from 11:10AM ET on Tuesday Nov 05, 2024 by Dow Jones
11:10AM ET on Tuesday Nov 05, 2024 by Dow Jones
Oct 30, 2024
DJ Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group, from 11:07AM ET on Wednesday Oct 30, 2024 by Dow Jones
11:07AM ET on Wednesday Oct 30, 2024 by Dow Jones
Oct 29, 2024
DJ Kiniksa Pharmaceuticals Down Over 12%, on Pace for Largest Percent Decrease Since August 2021 -- Data Talk, from 11:09AM ET on Tuesday Oct 29, 2024 by Dow Jones
11:09AM ET on Tuesday Oct 29, 2024 by Dow JonesKiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution, from 7:30AM ET on Tuesday Oct 29, 2024 by Dow Jones
7:30AM ET on Tuesday Oct 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.5B | -134.4x | --- |
Dynavax Technologies Corp | 1.6B | 100.0x | --- |
BioCryst Pharmaceuticals Inc | 1.5B | -11.6x | --- |
CareDx Inc | 1.1B | -7.8x | --- |
MiMedx Group Inc | 1.4B | 18.7x | --- |
Maravai LifeSciences Holdings Inc | 1.1B | -2.7x | --- |
Company Information
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Contact Information
- Headquarters
- Clarendon House, 2 Church StreetHAMILTON, Bermuda HM11
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Sanjiv Patel
- Chief Financial Officer, Senior Vice President
- Mark Ragosa
- Chief Operating Officer, Senior Vice President
- Eben Tessari
- Senior Vice President, Chief Commercial Officer
- Ross Moat
- Senior Vice President, Chief Medical Officer
- John Paolini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.5B |
|---|---|
Revenue (TTM) | $384.1M |
Shares Outstanding | 72.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.26 |
EPS | $-0.16 |
Book Value | $6.23 |
P/E Ratio | -134.4x |
Price/Sales (TTM) | 4.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6.83% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
